The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome.

Abstract

Elevated levels of oxidative nucleic acid modifications have been proposed to be associated with some of the clinical characteristics of Down syndrome. Oral intake of coenzyme Q10 improves oxidative status and shows a tendency toward protective effect on DNA oxidation in certain age groups of children with Down syndrome. Here, we demonstrate that long-term (i.e., 4 years) treatment with coenzyme Q10 (ubiquinone) at the dosage of 4 mg/kg/d does not affect whole body DNA and RNA oxidation.

• Authors: Emil List Larsen, Lucia Padella, Helle Kirstine Mørup Bergholdt, Trine Henriksen, Lucia Santoro, Orazio Gabrielli, Henrik Enghusen Poulsen, Gian Paolo Littarru, Patrick Orlando, Luca Tiano
• Journal: Neurobiology of aging (Neurobiol Aging) Vol. 67 Pg. 159-161 (07 2018) ISSN: 1558-1497 [Electronic] United States
• PMID: 29665577 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018 Elsevier Inc. All rights reserved.

Chemical References

• Biomarkers
• Deoxyadenosines
• Ubiquinone
• 8-hydroxyguanine
• Guanine
• 2'-deoxy-7,8-dihydro-8-oxoadenosine
• RNA
• DNA
• coenzyme Q10

Topics

• Administration, Oral
• Biomarkers (urine)
• Child
• DNA (metabolism)
• Deoxyadenosines (urine)
• Down Syndrome (drug therapy, etiology, metabolism)
• Guanine (analogs & derivatives, urine)
• Humans
• Oxidation-Reduction (drug effects)
• Oxidative Stress (drug effects)
• RNA (metabolism)
• Time Factors
• Ubiquinone (administration & dosage, analogs & derivatives, pharmacology)